Список проголосовавших за комментарий " Sector Summary: The Healthcare sector (+0.72%) is trading higher today, outperfomring the S&P 500 (-0.14%)<strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>Aurinia (<strong>AUPH</strong> +6.23%) Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial</li><li>Immunomedics (<strong>IMMU</strong> +1.53%) issues a statement to stockholders and announced it has filed an investor presentation with the SEC titled «The Right Board and the Right Strategy to Maximize Stockholder Value»</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>Novan (<strong>NOVN</strong> -77.01%) announces mixed top-line results from its two Phase 3 trials for SB204 in the treatment of acne vulgaris</li><li>Athersys (<strong>ATHX</strong> -29.61%) prices underwritten public offering of 19,802,000 shares of its common stock at $1.01/share</li><li>K2M Group (<strong>KTWO</strong> -4.93%) announces offering of 4 mln shares of its common stock by Welsh, Carson, Anderson & Stowe XI, L.P. and certain related affiliates</li></ul><strong><span style="color:#228822;">Gainers on earnings:</span></strong><br/> <ul><li>C.R. Bard (<strong>BCR</strong> +5.47%) beats by $0.03, beats on revs; guides FY17 EPS above consensus, revs in-line</li><li>Abaxis (<strong>ABAX</strong> +3.73%) misses by $0.01, reports revs in-line with 1/10/2016 pre-announcement</li></ul><strong><span style="color:#ff0000;">Decliners on earnings:</span></strong><br/> <ul><li>Select Medical (<strong>SEM</strong> -3.62%) sees Q4 revs $1.05 bln vs $1.05 bln Capital IQ Consensus Estimate; sees Q4 Adjusted EBITDA of $92-102 mln</li><li>OpGen (<strong>OPGN</strong> -3.24%) sees Q4 revs of ~$1 mln vs $1.10 mln single analyst estimate, sees Q4 net loss in the range of approximately $4.6-5.1 mln</li><li>AbbVie (<strong>ABBV</strong> -2.35%) reports EPS in-line, misses on revs; guides FY17 EPS in-line</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>Mateon Therapeutics (<strong>MATN</strong> +7.69%) initiated with a Buy at Maxim Group; tgt $2</li><li>Neurocrine Biosci (<strong>NBIX</strong> +2.26%) upgraded to Outperform from Perform at Oppenheimer</li><li>Clovis Oncology (<strong>CLVS</strong> +1.98%) initiated with a Buy at BofA/Merrill; tgt $74</li><li>Theravance Biopharma (<strong>TBPH</strong> -1.02%) initiated with a Sell at Empire; $16 tgt</li><li>Acadia Healthcare (<strong>ACHC</strong> -1.31%) downgraded to Neutral from Overweight at Cantor Fitzgerald</li></ul>"